Mechanism of Action
- Interacts with MUC2 mucin in intestinal goblet cell secretions, reinforcing the mucus gel barrier
- Promotes rapid epithelial restitution (cell migration into wounded areas) within hours of injury via FAK/Src/PI3K activation
- Anti-apoptotic: protects intestinal epithelial cells from cytokine-induced and irradiation-induced apoptosis via NF-kB pathway
- Reduces intestinal permeability and tight junction disruption during inflammatory challenge
- Stimulates goblet cell differentiation and mucin gene expression in intestinal progenitor cells
Research Findings
- TFF3 knockout mice show dramatically impaired colonic mucosal healing after dextran sodium sulfate (DSS) colitis, with higher mortality
- Recombinant TFF3 enema or oral administration reduced severity and accelerated healing in DSS colitis and TNBS colitis models
- TFF3 levels markedly reduced in active inflammatory bowel disease (Crohn and ulcerative colitis) mucosa
- TFF3 clinical trial (oral recombinant ITF): reduced gut permeability and diarrhea severity in AIDS enteropathy patients
- TFF3 combined with oral rehydration solution (ORS) improved outcomes vs ORS alone in childhood diarrhea clinical trial
Research Protocols
- DSS colitis mouse model: 0.5-5 mg/kg oral or rectal TFF3 daily for 7-14 days
- Human clinical trials: oral recombinant TFF3 at 0.5-3 g/day (as luminal doses for IBD/AIDS enteropathy)
- Enema: 50-200 mg recombinant TFF3 per enema for distal colitis in pilot studies
- In vitro migration assay: 10-100 ng/mL TFF3 on Caco-2 or IEC-6 intestinal cell monolayer wound scratch
Interactions
Safety Profile
Well tolerated in animal and early clinical studies. Oral recombinant TFF3 at gram doses produced no significant systemic adverse effects. Potential concern: elevated serum TFF3 in some cancers (gastric, breast) may reflect escape from tumor suppression; therapeutic use targets mucosal not systemic doses.
Legal & Regulatory
Investigational; advanced clinical development for IBD and childhood diarrhea in some regions